RT Journal Article
SR Electronic
T1 Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3933
OP 3939
VO 37
IS 7
A1 FUMINORI ISHII
A1 YOICHIRO YOSHIDA
A1 YASUSHI YAMAUCHI
A1 NAOYA AISU
A1 DAIBO KOJIMA
A1 TOSHIYUKI MERA
A1 DAISUKE KATO
A1 TOSHIHIRO TANAKA
A1 KEIKO NAITO
A1 KOSEI YASUMOTO
A1 TAKASHI KAMIGAKI
A1 SHIGENORI GOTO
A1 YOSHIHIRO HAMADA
A1 SATOSHI NIMURA
A1 SHOHTA KODAMA
A1 SUGURU HASEGAWA
YR 2017
UL http://ar.iiarjournals.org/content/37/7/3933.abstract
AB Background/Aim: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. Patients and Methods: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included. Results: The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases. Conclusion: Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely.